graphic AMP program word cloud

In 2014, the National Institutes of Health, the Foundation for the NIH, the U.S. Food and Drug Administration, pharmaceutical companies, and nonprofit organizations created the Accelerating Medicines Partnership® (AMP®). This program seeks to transform the current model for developing diagnostics and treatments by increasing efficiency, improving the process, and increasing the number and effectiveness of new targeted therapies.

Learn more about the AMP Program.

NIAMS participates in three AMP programs:

AMP Autoimmune and Immune-Mediated Diseases (AMP® AIM) program

Launched in 2021, AMP AIM broadens and builds upon the earlier AMP RA/SLE program, described below. AMP AIM investigators are studying the cellular interactions and biological pathways that cause inflammation, injury, abnormal function, and clinical disease in rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and Sjögren’s disease.

Learn more about AMP AIM.

AMP Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) program 

Actively funded from 2014-2022, AMP RA/SLE investigators examined the cell types, gene expression patterns, and signaling molecules that play a role in rheumatoid arthritis (RA) and/or systemic lupus erythematosus (SLE). As the datasets gathered from the program are finalized, they will be added to NIAMS’ Arthritis and Autoimmune and Related Diseases Knowledge (ARK) Portal.

Learn more about AMP RA/SLE

chart showing AMP and AMP AIM timeline

Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP® BGTC)

The BGTC is establishing platforms and standards to speed the development and delivery of customized or “bespoke” gene therapies that could treat millions of people affected by rare diseases, including diseases too rare to be of commercial interest. In May 2023, the Consortium selected eight rare diseases for its clinical trial portfolio. The National Center for Advancing Translational Sciences is spearheading the effort at NIH.

Learn more about AMP BGTC.


Accelerating Medicines Partnership and AMP are registered service marks of the U.S. Department of Health and Human Services.

Last Updated: